...
首页> 外文期刊>International Journal of Pharmaceutical Sciences Review and Research >IN VITRO AND IN VIVO EVALUATION OF OKRA POLYSACCHARIDE-BASED COLON-TARGETED DRUG DELIVERY SYSTEMS
【24h】

IN VITRO AND IN VIVO EVALUATION OF OKRA POLYSACCHARIDE-BASED COLON-TARGETED DRUG DELIVERY SYSTEMS

机译:俄克拉基于多糖的结肠靶向药物输送系统的体外和体内评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Colon targeted tablet formulation was developed using okra polysaccharide (Abelmuschus esculentus) as a microbially triggered material and also as the carrier. Okra polysaccharide was isolated from Abelmuschus esculentus and used for tablet formulation with Ibuprofen as model drug. The matrix tablets with four different proportions of the okra (20%, 30%, 40% & 50%) with 1% ethyl cellulose in all the four formulations and the formulations were coded as WO1, WO2, WO3, & WO4. In all the formulations constant 100 mg Ibuprofen were incorporated. The formulations were evaluated for their hardness, weight variation, friability, and drug content and were characterized by FTIR. Matrix tablets were subjected to in vitro drug release studies. The release studies were carried out for 2 hours in pH 1.2, 3 hours in pH 7.4 phosphate buffer and for 10 hours in pH 6.8 PBS. The % Release of these formulations i.e. WO1, WO2, WO3 & WO4 were found to be 20.75, 18.48, 13.37 & 11.99 respectively at 5th hour. The fifth matrix tablet (WO5) with 10% ethyl cellulose, 40% okra polysaccharide and 100 mg ibuprofen was formulated. The % cumulative release of this formulation (WO5) was found to be 4.59 at 5th hour. Among the above, WO3 was chosen as the optimized formulation for further studies. The in vitro dissolution studies were carried out with pH 1.2, pH 7.4 and the study continued in pH 6.8 PBS with rat cecal matter at 6th hour in simulated colonic fluid in order to mimic conditions from mouth to colon. The post five hour studies were carried out without rat cecal also as a control. The observation made was that the maximum release was 98.09% at 10th hour with rat cecal matter and a mere 32.70 % and 46.98% without rat cecal matter at 8th and 10th hour respectively. These findings were confirmed by in vivo investigation using X-ray images of rabbits ingested with okra matrix tablets (WO5) containing barium sulphate as contrast medium instead of Ibuprofen. The tablet began to disintegrate at 8th hour of tablet ingestion. These observations drive us to conclude that the okra polysaccharide under investigation has the potential to carry the drug almost intact to the intended site i.e. Colon where it undergoes degradation due to the presence of anaerobic microbes there. Thereby both the aims contemplated are achieved.
机译:使用秋葵多糖(Abelmuschus esculentus)作为微生物触发的材料以及载体,开发了结肠靶向片剂。黄秋葵多糖从Abelmuschus esculentus中分离出来,并以布洛芬为模型药物用于片剂配制。在所有四种制剂中,具有四个不同比例的秋葵(20%,30%,40%和50%)和1%乙基纤维素的基质片剂,该制剂编码为WO1,WO2,WO3和WO4。在所有制剂中均掺入恒定的100mg布洛芬。评价制剂的硬度,重量变化,脆性和药物含量,并通过FTIR表征。对基质片剂进行了体外药物释放研究。在pH 1.2下进行释放研究2小时,在pH 7.4磷酸盐缓冲液中进行3小时,在pH 6.8 PBS中进行10小时。发现这些制剂即WO1,WO2,WO3和WO4在第5小时的释放%分别为20.75、18.48、13.37和11.99。配制含有10%乙基纤维素,40%秋葵多糖和100 mg布洛芬的第五种基质片剂(WO5)。发现该制剂(WO5)在第5小时的累积释放%为4.59。其中,WO3被选作进一步研究的优化制剂。在pH 1.2,pH 7.4的条件下进行了体外溶出研究,并在模拟结肠液中于第6小时在pH 6.8 PBS和大鼠盲肠中继续研究,以模拟从口腔到结肠的状况。五小时后的研究在没有大鼠盲肠的情况下进行,也作为对照。观察到,在有大鼠盲肠的情况下,在第10小时的最大释放量为98.09%,在无大鼠盲肠的情况下,在第8和10小时分别仅为32.70%和46.98%。通过使用含硫酸钡作为造影剂而非布洛芬的秋葵基质片剂(WO5)摄入的兔子的X射线照片进行体内研究,证实了这些发现。片剂摄入第8小时后片剂开始崩解。这些观察结果驱使我们得出结论,所研究的秋葵多糖具有将药物几乎完整地携带到预定部位的潜力,即结肠,由于那里存在厌氧微生物而使其降解。从而实现了预期的两个目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号